Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 201… Read more
Market Cap & Net Worth: Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Liminatus Pharma, Inc. Class A Common Stock (NASDAQ:LIMN) has a market capitalization of $5.98 Million ($5.98 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #35967 globally and #11696 in its home market, demonstrating a -1.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Liminatus Pharma, Inc. Class A Common Stock's stock price $0.23 by its total outstanding shares 26014600 (26.01 Million).
Liminatus Pharma, Inc. Class A Common Stock Market Cap History: 2025 to 2026
Liminatus Pharma, Inc. Class A Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $15.87 Million to $5.98 Million (0.00% CAGR).
Liminatus Pharma, Inc. Class A Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Liminatus Pharma, Inc. Class A Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LIMN by Market Capitalization
Companies near Liminatus Pharma, Inc. Class A Common Stock in the global market cap rankings as of March 19, 2026.
Key companies related to Liminatus Pharma, Inc. Class A Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Liminatus Pharma, Inc. Class A Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Liminatus Pharma, Inc. Class A Common Stock's market cap moved from $15.87 Million to $ 5.98 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.98 Million | -62.30% |
| 2025 | $15.87 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Liminatus Pharma, Inc. Class A Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.98 Million USD |
| MoneyControl | $5.98 Million USD |
| MarketWatch | $5.98 Million USD |
| marketcap.company | $5.98 Million USD |
| Reuters | $5.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.